Krystal Biotech, Inc. (KRYS) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Krystal Biotech, Inc. (KRYS) closed at USD 330.69 on 2026-10-14, a change of +74.4 % over the past year, with a market capitalization of USD 9.77B.
Krystal Biotech, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 330.69 |
| 2026-10-13 | 321.16 |
| 2026-10-12 | 332.07 |
| 2026-10-09 | 331.61 |
| 2026-10-08 | 327.30 |
| 2026-10-07 | 324.57 |
| 2026-10-06 | 326.81 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Krystal Biotech, Inc. key figures
- Previous close
- USD 330.69 (2026-10-14)
- 1-year change
- +74.4 %
- Market cap
- USD 9.77B
- Enterprise value
- USD 8.93B
- P/E ratio (trailing)
- 40.24
- P/E ratio (forward)
- 36.65
- EPS (trailing)
- 8.20
- EPS (forward)
- 9.00
- PEG ratio
- n/a
- Price to book
- 7.19
- Revenue growth
- 24.1 %
- Earnings growth
- 38.8 %
- Dividend per share (trailing)
- 0.00
- Short ratio
- 12.53
- Employees
- 295
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Krystal Biotech, Inc. and compare it with other stocks.
Analyze KRYSAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Krystal Biotech, Inc. shares.